Global Markets
Home›Global Markets›North America›Symbiotec Pharmalabs IPO opens with 42% grey market pr…
Symbiotec Pharmalabs IPO opens with 42% grey market premium
The IPO targets ₹1,757 crore, with ₹150 crore from fresh shares and ₹1,607 crore via an offer for sale, while bidding runs until 26 August 2026.
Symbiotec Pharmalabs Ltd has opened its initial public offering, with the public issue set to run through 26 August 2026, according to LiveMint Markets.
The company has set its price band at ₹938 to ₹988 per equity share, and the IPO size is ₹1,757 crore, made up of ₹150 crore from fresh shares and ₹1,607 crore reserved for an offer for sale route.
LiveMint Markets said grey market indications point to a listing gain, with the shares available at a premium of ₹411, which implies about a 42% pop versus the upper end of the offer price range.
The registrar for the book-built issue is MUFG Intime India Private Ltd, the issue is proposed for listing on BSE and NSE, with a tentative allotment date of 27 August 2026 and a likely listing date of 1 September 2026.